Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 99200-09-6
Drug Levels and Effects
Summary of Use during Lactation
Because no information is available on the use of nebivolol during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
The excretion of beta-adrenergic blocking drugs into breastmilk is largely determined by their protein binding. Those with low binding are more extensively excreted into breastmilk.[1] Accumulation of the drugs in the infant is related to the excretion rate. With 98% protein binding and a relatively long half-life, nebivolol presents a moderate risk for accumulation in infants.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Riant P, Urien S, Albengres E, et al. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol. 1986;35:4579–81. [PubMed: 2878668]
Substance Identification
Substance Name
Nebivolol
CAS Registry Number
99200-09-6
Drug Class
Breast Feeding
Adrenergic beta-Antagonists
Antihypertensive Agents
Vasodilator Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Structure and absolute configuration of two stereoisomers of alpha,alpha'-[iminobis-(methylene)]bis(3,4-dihydro-2H-1-benzopyran-2- methanol) hydrobromide.[Acta Crystallogr C. 1989]Structure and absolute configuration of two stereoisomers of alpha,alpha'-[iminobis-(methylene)]bis(3,4-dihydro-2H-1-benzopyran-2- methanol) hydrobromide.Peeters OM, Verlinde CL, Blaton NM, De Ranter CJ. Acta Crystallogr C. 1989 Dec 15; 45 ( Pt 12):1930-3.
- Synthesis and pharmacological properties of nebivolol, a new antihypertensive compound.[J Pharm Belg. 1990]Synthesis and pharmacological properties of nebivolol, a new antihypertensive compound.Van Lommen G, De Bruyn M, Schroven M. J Pharm Belg. 1990 Nov-Dec; 45(6):355-60.
- Review Ropinirole.[Drugs and Lactation Database (...]Review Ropinirole.. Drugs and Lactation Database (LactMed®). 2006
- Review Quazepam.[Drugs and Lactation Database (...]Review Quazepam.. Drugs and Lactation Database (LactMed®). 2006
- Review Tedizolid.[Drugs and Lactation Database (...]Review Tedizolid.. Drugs and Lactation Database (LactMed®). 2006
- Nebivolol - Drugs and Lactation Database (LactMed®)Nebivolol - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...